<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339441</url>
  </required_header>
  <id_info>
    <org_study_id>10H101429</org_study_id>
    <nct_id>NCT02339441</nct_id>
  </id_info>
  <brief_title>Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis</brief_title>
  <acronym>ESOS</acronym>
  <official_title>Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manchester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the effectiveness of commonly used immunosuppressant
      treatments for early diffuse cutaneous systemic sclerosis (SSc).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diffuse cutaneous systemic sclerosis (SSc) is a rare autoimmune disease characterised by
      excessive connective tissue in the skin (causing skin thickening called 'scleroderma'),
      muscle, joints and internal organs. A number of different drugs with effects on the immune
      system (known as 'immunosuppressants') are currently being used by clinicians in the
      treatment of early diffuse cutaneous SSc, but all can have significant side effects. We want
      to know whether any one is definitely effective and, if so, which is the most effective.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Skin score as measured by modified rodnan skin score</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function as measured by right ventricular systolic pressure (RVSP) or pulmonary artery pressure (PAP)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic findings</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cochin hand function</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT) scale</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short form 36 questionnaire (SF-36)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scleroderma Health Assessment Questionnaire</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte sedimentation rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">320</enrollment>
  <condition>Early Diffuse Cutaneous Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <description>Patients treated with Methotrexate at the entry of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <description>Patients treated with Mycophenolate Mofetil at the entry of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <description>Patients treated with Cyclophosphamide at the entry of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Immunosuppressant</arm_group_label>
    <description>Patients without immunosuppressant treatment at the entry of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.</description>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.</description>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligibility:

        Age &gt; 18 Skin thickening &lt; 3 years Immunosuppressant use &lt; 4 months Proximal skin
        involvement to face/neck, elbow or knee
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age &gt; 18 Skin thickening &lt; 3 years Immunosuppressant use &lt; 4 months Proximal skin
        involvement to face/neck, elbow or knee

        Exclusion Criteria:

        Previous use of more than 4 months of methotrexate, mycophenolate mofetil, cyclophosphamide
        or other immunosuppressive treatments

        Previous use of immunosuppressant therapy other than methotrexate, mycophenolate mofetil or
        cyclophosphamide within previous months

        Previous stem cell transplantation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariane Herrick, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2015</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manchester</investigator_affiliation>
    <investigator_full_name>Prof. Ariane herrick</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

